🇺🇸 TLK286 in United States
26 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 28 March 2025 – 28 March 2026
- Total reports: 26
Most-reported reactions
- Anaemia — 5 reports (19.23%)
- Malignant Neoplasm Progression — 4 reports (15.38%)
- Pancytopenia — 3 reports (11.54%)
- Cardio-Respiratory Arrest — 2 reports (7.69%)
- Febrile Neutropenia — 2 reports (7.69%)
- Hypotension — 2 reports (7.69%)
- Intestinal Obstruction — 2 reports (7.69%)
- Mental Status Changes — 2 reports (7.69%)
- Pleural Effusion — 2 reports (7.69%)
- Pneumonia — 2 reports (7.69%)
Frequently asked questions
Is TLK286 approved in United States?
TLK286 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for TLK286 in United States?
Telik is the originator. The local marketing authorisation holder may differ — check the official source linked above.